Archive for the ‘research’ Category

New Study: HCQ & Zinc Greatly Reduces COVID-19 Health Risk

https://principia-scientific.org/new-study-hydroxychloroquine-zinc-greatly-reduces-covid-19-health-risk/

New Study: Hydroxychloroquine + Zinc Greatly Reduces COVID-19 Health Risk

Published on

Written by dcwhispers.com

While the main stream media yet again is pushing recycled headlines about a New York “study” of very ill patients who were NOT actually given the combination of hydroxychloroquine and zinc which concluded these near-death patients did no better or worse when given the drug, another study showing a very different result was largely ignored by these same media outlets.

Imagine that.

Check out this headline coming out of New York as well which showed the combination of hydroxychloroquine and zinc slashed the risk of death from the coronavirus by nearly half.

**Drug Combo With Hydroxychloroquine Promising: NYU Study**

NEW YORK – Researchers at NYU’s Grossman School of Medicine found patients given the antimalarial drug hydroxychloroquine along with zinc sulphate and the antibiotic azithromycin were 44 percent less likely to die from the coronavirus.

“Researchers at NYU’s Grossman School of Medicine found patients given the antimalarial drug hydroxychloroquine along with zinc sulphate and the antibiotic azithromycin were 44 percent less likely to die from the coronavirus.

“Certainly we have very limited options as far as what we have seen work for this infection so anything that may work is very exciting,” said Dr. Joseph Rahimian, Infectious Disease Specialist at NYU Langone Health.”

The study looked at the records of 932 COVID-19 patients treated at local hospitals with hydroxychloroquine and azithromycin.

More than 400 of them were also given 100 milligrams of zinc daily.

Researchers Said The Patients Given Zinc Were One And A Half Times More Likely To Recover, Decreasing Their Need For Intensive Care.

If one were to do an online news search right now for similar studies as above you will find story after story on the recycled New York study that showed no benefit from hydroxychloroquine while this other study (also from New York) that indicates the hydroxychloroquine + zinc combination shows remarkable promise, is receiving almost zero media coverage.

This is the same combination that has been touted by physicians all across America and the world as proving highly effective and yet here in the U.S. there are forces both in government and the media who continue to push this success to the side while also pushing yet more fear and panic of the disease.

Did you know that in Italy, one of the nations hardest hit by Covid 19, once doctors started initiating mass use of hydroxychloroquine and zinc, the death rate plummeted from a high of nearly a thousand a day to less than 200? This drug combination protocol has been repeated in other nations like South Korea, France, Bahrain, Turkey, Brazil, etc., with similar rates of success there as well as outlined in this excerpt from an April 21st scientific journal release:

“On March 23, 2020 a physician (Vladimir Zelenko) in Monroe, New York state, published online similar excellent outcomes on treating his patients with shortness of breath and any patient in the high-risk category with HCQ, azithromycin and zinc sulfate for five days in order to prevent hospitalization.

On April 17, 2020 doctors from a health care provider focused on mostly elderly and chronic patients in Brazil confirmed Raoul’s and Zelenko’s findings reporting that out of 636 symptomatic outpatients of the 224 who refused treatment (control group), 12 were hospitalized (5.4%), and of these 12 hospitalized, 5 patients died (41%) [12]. On the other hand, of the 412 outpatients treated with HCQ and azithromycin, only 8 were hospitalized (1.94%), and no deaths were observed. In case of early treatment (<7 days of symptoms) only 1.17% of treated patients needed hospitalization, while the percentage raised to 3.2% for late treatment (>7 days of symptoms). These outcomes were even more remarkable considering that patients in the treatment groups had higher prevalence of comorbidities including diabetes, immunosuppression state and stroke [12]. “

Again, why is there such push-back going on in the United States from the far-left media to dismiss what appears to be the undeniable effectiveness of hydroxychloroquine + zinc in combatting Covid-19?

Something very weird is going on here and people have been dying by the thousands because of it.

Good news, possibly life-saving news, is being pushed aside while bad news, not matter how flawed or biased, is put front and center in an effort to convince tens of millions that there is currently no real treatment options for the coronavirus even as so much data out there appears to say that is simply not so.

Read more at www.ny1.com

__________________________

**Comment**

For the reason why the media and “authorities” badmouth HCQ:   https://principia-scientific.org/a-tale-of-2-drugs-deep-state-chose-money-power-over-lives/

Excerpt:

Approximately $70 million in U.S. taxpayer funding began Gilead’s partnership with the U.S. Army, Centers for Disease Control and Prevention (CDC) and National Institutes of Health (NIH) to develop remdesivir. Initially for treating Ebola, it failed to show benefit and was shelved. If remdesivir is used to treat COVID-19, Gilead shareholders, not the taxpayers, will profit.

HCQ directly competes with the favored profitable treatment of remdesivir.

In fact the article states that 9 of the 19 experts on the COVID-19 treatment panel have financial interests in Gilead Science.  See the problem?

Early results of the first clinical trial of remdesivir against placebo in coronavirus showed modest benefits, according to The New York Times. Surviving patients given remdesivir were discharged four days sooner than patients given placebo, though no criteria were given for determining improvement. Death rates were not significantly different. About 25% of patients receiving remdesivir had potentially severe side effects, including multiple organ dysfunction, septic shock, acute kidney injury and low blood pressure. Another 23% showed evidence on lab tests of liver damage.

Gilead’s own press release revealed the side effect of acute respiratory failure in 6% of patients in the remdesivir five-day treatment group, and 10.7% of patients in the 10-day treatment group, clearly ominous findings with a drug designed to treat respiratory failure caused by COVID-19.

Dr. Steven Nissen, a Cleveland Clinic cardiologist who has conducted dozens of clinical trials, explained to The New York Times:

“The disclosure of trial results in a political setting, before peer review or publication, is very unusual. Scientists will need to see figures on harms associated with the drug in order to assess its benefits. … This is too important to be handled in such a sloppy fashion.”

Going back to 1997, Donald Rumsfeld chaired the Board of Directors at Gilead and after 2001 he held share packages valued at $5-25 Million. Gilead originally developed Tamiflu. George P Shultz, US Secretary of State also was on the board. He sold stocks at a value of more than $7 million. CA governor’s Pete Wilson’s wife also sat on the board.

“‘I don’t know of any biotech company that’s’ so politically well-connected [as Gilead],‘ Andrew McDonald, of the analyst firm Think Equity Partners, told Fortune.” (Source: “Virus Mania, How the Medical Industry Continually Invents Epidemics Making Billion Dollar Profits At Our Expense”)

Shunning competing tests and treatments if what the CDC does:  https://madisonarealymesupportgroup.com/2020/04/26/cdc-playbook-learning-from-lyme/

These fraudsters need to go to jail.  Contact your representatives and senators:  https://madisonarealymesupportgroup.com/2020/05/20/cdc-crimes-possible-sherman-provisions-clayton-acts-violated/

 

 

 

 

Category:

research, Treatment, Viruses

Morgellons NOT Associated With Fungus

  Approx. 1 Hour 15 Min.

Morgellons NOT Associated With Fungus

May 17, 2020

Interview with microbiologist Marianne Middleveen.

For more:  https://madisonarealymesupportgroup.com/2020/02/24/classification-staging-of-morgellons-disease-lessons-from-syphilis/

https://madisonarealymesupportgroup.com/2020/02/15/morgellons-disease-foundation-goes-skin-deep-with-groundbreaking-documentary/

https://madisonarealymesupportgroup.com/2019/05/29/mixed-borrelia-burgdorferi-helicobacter-pylori-biofilms-in-morgellons-disease-dermatological-specimens/

https://madisonarealymesupportgroup.com/2016/06/17/morgellons-believe-it/

https://madisonarealymesupportgroup.com/2016/10/27/research-on-morgellons/

https://madisonarealymesupportgroup.com/2016/12/10/morgellons-in-dogs/

https://madisonarealymesupportgroup.com/2019/08/19/interview-marianne-middelveen-on-morgellons/

https://madisonarealymesupportgroup.com/2018/03/05/morgellons-not-a-delusion-states-new-study/

https://madisonarealymesupportgroup.com/2019/11/20/interview-with-morgellons-expert-dr-ginger-savely/

 

Category:

Lyme, Morgellons, research

Chronic Neurological Lyme Disease Or Co-Morbid Conditions?

https://danielcameronmd.com/chronic-neurological-lyme-disease-dismissed-for-co-morbid-conditions/

CHRONIC NEUROLOGICAL LYME DISEASE OR CO-MORBID CONDITIONS?

man with fatigue holding head

Some patients with chronic neurological Lyme disease continue to have persistent, debilitating symptoms following treatment.

A recent study confirmed the severity of chronic symptoms in this patient population but unfortunately dismissed the symptoms, attributing them to various co-morbid conditions, rather than Lyme disease. [1]

By

 

The study, “Patient-reported outcome after treatment for definite Lyme neuroborreliosis” by Eikeland and colleagues, describes 258 patients treated for definite Neurologic Lyme disease. Many of them remained symptomatic an average of 5 years after their initial treatment.

According to the authors, a higher proportion of their chronic neurological Lyme disease patients reported severe fatigue. Furthermore, “Mental health-related quality of life was poorer among [neuroborreliosis] NB-treated patients than in normative data.”

Although many of the patients’ symptoms are consistent with those found in chronic neurological Lyme disease, the authors attributed the symptoms to co-morbid illnesses, based on a retrospective review of the medical records.

READ MORE: Six cases of neuroinvasive Lyme disease

The symptoms included: radiating pain, general pain, fatigue, facial palsy, malaise, dizziness and/or unsteadiness, headache, numbness in arm and/or leg, memory and/or concentration problems, paresis in arm and/or leg, and diplopia.

Symptoms due to chronic neurological Lyme disease or co-morbid conditions? CLICK TO TWEET 

Co-morbid conditions listed for these patients included: fibromyalgia, allergies, depression or anxiety, multiple sclerosis, systemic disease sarcoidosis, systemic lupus erythematosus, Sjögren’s syndrome, rheumatoid arthritis, chronic fatigue syndrome, Parkinson’s disease, thyroid dysfunctions, and cancer.

Note: The study was not designed to assess whether the patient, in fact, had the co-morbidity listed in their records or instead had complications of chronic neurological Lyme disease.
Related Articles:

Neurological damage/dysfunction found in early Lyme disease patients

Case report: Lyme neuroborreliosis more common in children

Fatal case of neuroborreliosis

References:
  1. Eikeland R, Ljostad U, Helgeland G, et al. Patient-reported outcome after treatment for definite Lyme neuroborreliosis. Brain Behav. 2020:e01595.

____________________

**Comment**

Another worthless study to add to the ever increasing pile of trash.

These poor, sick people were given all sorts of labels: fibromyalgia, lupus, Sjogren’s, RA, CFS, Parkinson’s, cancer – the typical “bad guys,” but ALL were infected with Lyme disease which can cause symptoms indicative of those labels.

It’s very interesting that with Lyme disease, “authorities” want to blame anything other than a persistent borrelia infection, but with COVID-19, those same “authorities” want to blame everything on COVID-19.  This should smell bad to you.  This is not science – it’s biased, narrative-driven propaganda.

For more: Peer-Reviewed Evidence of Persistence of Lyme:MSIDS copy

https://madisonarealymesupportgroup.com/2020/03/09/the-long-term-persistence-of-borrelia-burgdorferi-antigens-dna-in-the-tissues-of-lyme-disease-patient/

https://madisonarealymesupportgroup.com/2017/05/10/body-of-research-showing-borrelia-persists/

https://madisonarealymesupportgroup.com/2020/04/08/how-do-lyme-disease-symptoms-persist-long-term/

https://madisonarealymesupportgroup.com/2019/07/31/post-lyme-disease-syndrome-vs-chronic-lyme-disease-syndrome/

https://madisonarealymesupportgroup.com/2018/04/13/chronic-lyme-post-mortem-study-needed-to-end-the-lyme-wars/

 

Category:

Lyme, research

Babesia Infection 3 Weeks After Lyme Treatment

https://danielcameronmd.com/lyme-podcast-a-babesia-infection-3-weeks-after-treatment-for-lyme-disease/

LYME PODCAST: A BABESIA INFECTION 3 WEEKS AFTER TREATMENT FOR LYME DISEASE.

A Babesia infection 3 weeks after treatment for Lyme disease.

I will discuss a 67-year-old woman with a Babesia infection 3 weeks after treatment for Lyme disease. Could this delay explain why some patients remain ill or relapse?

By

Podcast:

https://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkcy5idXp6c3Byb3V0LmNvbS83NzI

Hoversten and her colleague first discussed this case in the British Medical Journal Case Reports  in 2018.

One would expect that tick-borne infections would all occur at the same time.

One would be wrong, as this case illustrates.

A 67-year-old woman from Wisconsin had extensive exposure as an avid gardener and spent a considerable amount of time outdoors.

She did not see a tick. She did see a rash consistent with an erythema migrans rash.

A delay in onset of Babesia may explain why some Lyme disease patients relapse after initially improving with doxycycline or amoxicillin. CLICK TO TWEET

She was prescribed amoxicillin for three-weeks as she was allergic to doxycycline.

Near the end of three-week of amoxicillin, she became ill. Her fever rose to 102.9 F0. She complained of myalgias, dizziness, and fatigue.

Her blood test showed mild anemia, a low platelet count and neutrophil count, and a very high C-reactive protein.

  • neutrophil is a type of white blood cell that helps resolve infections and heal damaged tissues. A low neutrophil count can be seen in tick-borne diseases.
  • A high C-reactive protein is a marker for inflammation but cannot be used to determine what type of inflammation.

She was admitted to the hospital. The doctors thought she might be suffering from sepsis or a tick-borne infection.

  • Sepsis is a life-threatening illness caused by your body’s response to an infection.
  • Her red blood count and platelets continued to drop.
  • She was transferred to a second hospital.
  • There was no evidence of sepsis. The blood cultures were negative after five days.

BABESIA INFECTION

She was diagnosed with the parasite Babesia microti by PCR and by a thin smear of her red blood cells. Typically, Babesia microti is seen on a thick smear of blood. In her case, 0.4% of her red blood cells showed the parasite Babesia microti on a thin smear.

Babesia infections can be severe and, in rare cases, life-threatening. Babesia infections can also be mild or without symptoms. Babesia was more likely to be severe in this woman as she was over 50-years of age and had a history of colon cancer.

She was prescribed a 10-day course of azithromycin and atovaquone. By 5th day of treatment, her fever had resolved, and her platelet count had more than doubled from a low of 17,000 per dl to 42, 000 per dl.

The authors report that the woman remains fatigued after completing treatment.

The authors discussed the nearly three-week gap in time between the woman’s erythema migrans rash and her diagnosis of Babesia. This is not the first case where the onset of Babesia was delayed.

The authors cited two papers describing a 3 to 4-week delay in the onset of Babesia. I described a paper in an earlier podcast where two babies contracted Babesia from their mothers. They did not present with Babesia until after being discharged from the hospital. You can read more about these babies in the article by Saetre and colleagues or listen to my Inside Lyme podcast titled. “Two children who contacted Babesia from their mother.”

This delay may explain why some Lyme disease patients relapse after initially improving with doxycycline or amoxicillin. Treatment for Lyme disease with doxycycline or amoxicillin is not effective for the treatment of Babesia.

What can we learn from this cases?

  1. Babesia infections can occur weeks after the onset of Lyme disease.

What questions does these cases raise?

  1. Should the woman have been evaluated for Babesia infection at the time of the erythema migrans?
  2. Would a Babesia infection have been recognized if the woman had not been diagnosed with Lyme disease?
  3. Should Lyme disease patients be advised to return for follow-up?
  4. Would earlier treatment have avoided the need for hospitalization?
  5. What is the long-term outcome for this woman with a Babesia infection

TREATING TICK-BORNE DISEASE IN MY PRACTICE

In my practice, each individual requires a careful assessment. That is why I order a broad range of blood tests for other illnesses in addition to tick-borne infections. I also arrange consultations with specialists as needed.

Many patients are complex, as highlighted in this Inside Lyme Podcast series.

We need more doctors with skills recognizing Babesia in a patient with Lyme disease. We hope that professionals evaluating individuals with Lyme disease can use this case to remind them to look for Babesia with Lyme disease.

Inside Lyme Podcast Series

This Inside Lyme case series will be discussed on my Facebook and made available on podcast and YouTube.  As always, it is your likes, comments, and shares that help spread the word about this series and our work. If you can, please leave a review on iTunes or wherever else you get your podcasts.

Sign up for our newsletter to keep up with our cases.

_____________________

For more:  

Category:

Babesia, Lyme, research, Treatment

Podcast: Evidence Supporting HCQ & Azithromycin for COVID-19

COVID-19 PODCAST: HYDROXYCHLOROQUINE AND AZITHROMYCIN FOR COVID-19 MAY BE EFFECTIVE AFTER ALL.

Hydroxychloroquine and azithromycin for COVID-19

Welcome to my next Inside Lyme podcast. – I will examine the evidence supporting hydroxychloroquine and azithromycin for COVID-19.

By

Podcast:

https://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkcy5idXp6c3Byb3V0LmNvbS83NzI

You may be wondering why I am discussing COVID-19 during an Inside Lyme podcast. I am concerned for my children, grandchildren, and my patients. I want to share my understanding of COVID-19 through my eyes as a clinical epidemiologist.

COVID-19 is now a pandemic. We need an effective and safe drug to treat this virus.

Researchers have turned to existing drugs that might be effective without causing significant side effects. Hydroxychloroquine and chloroquine have been prescribed for the treatment and prophylaxis of malaria in addition to the treatment of autoimmune diseases. Hydroxychloroquine and azithromycin have also been prescribed for Lyme disease patients. Hydroxychloroquine and azithromycin have been marketed under the name Plaquenil and Zithromax, respectively in the US.

Both chloroquine and hydroxychloroquine have side effects. The most common side effect of hydroxychloroquine is nausea and diarrhea. In rare cases, hydroxychloroquine can lead to reduced white blood cells, platelets count, anemia, and retinopathy. Retinopathy can lead to color blindness and loss of vision. Both hydroxychloroquine and azithromycin can lead to sudden death from a prolonged QT interval.

ANTIVIRAL EFFECTS OF HYDROXYCHLOROQUINE AND CHLOROQUINE

Hydroxychloroquine and chloroquine have shown some antiviral benefits in vitro (Wang, 2020, letter) Both have been studied for other related viruses, including Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (Mers).

Chloroquine improved outcomes in a series of small studies in China. Gao and colleagues discussed the finding in the journal BioScience Trends .

“Thus far, results from more than 100 patients have demonstrated that chloroquine phosphate is superior to the control treatment in inhibiting the exacerbation of pneumonia, improving lung imaging findings, promoting a virus negative conversion, and shortening the disease course according to the news briefing.”

These findings led the State Council in China to approve chloroquine for COVIID-19

Hydroxychloroquine and azithromycin for COVID-19 may be effective after all. CLICK TO TWEETUnfortunately, this series of Chinese trials do not appear to have been published. It is hard to discuss these Chinese trials until they are published.

FIRST FRENCH CLINICAL TRIAL BY GAUTRET AND COLLEAGUES

Gautret and colleagues published a French trial evaluating the benefit and risks of hydroxychloroquine and Zithromax for the treatment of COVID-19.

The authors prescribed 600 mg of hydroxychloroquine to 26 patients with COVID-19. Two were asymptomatic. Ten had upper tract respiratory infections, and six had lower tract respiratory infections. The doctors prescribed azithromycin to 6 of their patients with COVID-19 to prevent bacterial superinfection.

The authors were able to show a significant reduction in the viral load in nasopharyngeal samples of their COID-19 patients treated with hydroxychloroquine compared to COVID-19 patients who were not treated.

The authors were able to show even a greater reduction in viral load in the six COVID-19 patients when Zithromax was added.

Only one of the 26 patients treated with hydroxychloroquine was dropped from the study due to an adverse event. That patient dropped out due to nausea.

The authors explained why they decided to share their findings early.

“For ethical reasons and because our first results are so significant and evident, we decide to share our findings with the medical community, given the urgent need for an effective drug against SARS-CoV-2 in the current pandemic context.”

FLAWS IN THE FIRST FRENCH TRIAL BY GAUTRET

The Gautret trial was small and flawed. They should have used controls from the same hospital with the same characteristics as the 26 treated patients. Instead, they enrolled 16 controls were from other centers.

The Gautret trial did not evaluate whether a reduction or elimination of the COVID-19 virus in saliva would prevent outcomes important to patients such as a transfer to an intensive care unit or death. Four of the 26 patients treated with hydroxychloroquine did poorly. Three were transferred to the intensive care unit. One died. None of the patients with a COVID—19 infection developed a QT prolongation.

The Gautret trial was not designed to determine if the absence if COVID-19 from the saliva meant the absence of COVID-19 from other tissues.

The Gautret trial could not determine if the benefits seen for the six COVID-19 patients treated with azithromycin were from an antiviral effect or an antibiotic effect.

SECOND FRENCH TRIAL

A recently published second French trial by Gautret and colleagues added further support for the hydroxychloroquine with azithromycin.

“In 80 in-patients receiving a combination of hydroxychloroquine and azithromycin we noted a clinical improvement in all but one 86 year-old patient who died, and one 74-year-old patient still in intensive care unit.”

PLANNED TRIALS

Researchers at the University of Minnesota are planning on a trial “to see whether malaria treatment hydroxychloroquine can prevent or reduce the severity of the coronavirus disease (COVID-19)” writes Gabe Gutierrez and Dennis Romero in NBCNews.

COULD CUTTING THE COVID-19 VIRAL LOAD BE HELPFUL?

Yes, according to Gautret. “hydroxychloroquine and azithromycin “can play a role in controlling the disease epidemic by limiting the duration of virus shedding, which can last for several weeks in the absence of specific treatment.” write Gautret.

COULD HYDROXYCHLOROQUINE AND AZITHROMYCIN FOR INDIVIDUALS WITH COVID-19 BE HELPFUL?

Yes, according to both Gautret trials. Hydroxychloroquine and azithromycin lowered the COVID-19 viral load patient. Moreover, most of the patients with a COVID-19 infection were improved or discharged in the second Gautret trial.

COULD HYDROXYCHLOROQUINE AND AZITHROMYCIN PREVENT COVID-19 INFECTION?

Neither Gautret trials assessed whether hydroxychloroquine with azithromycin would be effective for prophylaxis before an infection. The study only enrolled hospitalized patients already infected with the COVID-19 virus.

WHAT NOW?

For now, researchers and politicians are divided on whether to recommend hydroxychloroquine and azithromycin for the prevention and treatment of COVID-19. There is growing pressure on doctors to wait for science.

Doctors have patients who are sick now. Doctors have patients who want to prevent getting COVID-19.

“The Food and Drug Administration (FDA) on Sunday issued an emergency-use authorization for a pair of anti-malaria drugs as health officials work to combat the rapid spread of the novel coronavirus.” writes Jusin Wise in The Hill.

Stay tuned.

References:
  1. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271.
  2. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Dupont HT, Honoré S, Colson P, Chabrière E, La Scola B, Rolain JM, Brouqui P, Raoult D. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Mar 20:105949.
  3. Cai J, Xu J, Lin D, Yang Z, Xu L, Qu Z, Zhang Y, Zhang H, Jia R, Liu P, Wang X, Ge Y, Xia A, Tian H, Chang H, Wang C, Li J, Wang J, Zeng M. A Case Series of children with 2019 novel coronavirus infection: clinical and epidemiological features. Clin Infect Dis. 2020 Feb 28. pii: ciaa198
  4. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020 Mar 16;14(1):72-73.
  5. Gautret P, Lagier JC, Parola P, and colleagues. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: an observational study. To be published as of 3/20/20.
  6. Clinical trials on coronavirus drugs may take only months, researcher says. Gabe Gutierrez and Dennis Romero, From NBCNew.com Last accessed 3/29/20.

_____________

**Comment**

I posted this recently, but “authorities” have been bad-mouthing HCQ because many of them are getting financial kick-backs from Gilead Science, the manufacturer of the anti-viral Remdesivir, which bombed for Ebola, so they dug it out of the drug graveyard and are repurposing it for COVID-19.  HCQ is a direct competitor and the CDC/NIH won’t have it.  They diss any test or treatment that competes with their own.  It’s all about profits. This is why nothing will change until these people can not have patents and conflicting interests.  See:  https://madisonarealymesupportgroup.com/2020/05/08/update-cdc-playbook-learning-from-lyme/

When I compare how the media writes about the anti-viral drug Remdesivir vs HCQ, it isn’t surprising to learn that NIAID is working with Gilead to conduct Phase II human trials on on it.  Dr. Fauci, who is supposed to be a gate-keeper of public health, often does business with Big Pharma:  https://www.fort-russ.com/2020/04/shedding-light-on-the-dishonorable-record-of-dr-fauci-a-real-mengele/

Please see Dr. Eric Berg‘s FB video explaining HCQ vs Remdesivir:  https://www.facebook.com/135796882846/posts/10158628517062847/?sfnsn=mo&d=n&vh=e

Even the White House economic adviser got into a massive argument with Fauci over his ongoing resistance to the use of hydroxychloroquine to treat COVID-19:  https://madisonarealymesupportgroup.com/2020/04/08/peter-navarro-explodes-at-fauci-in-heated-showdown-over-hydroxychloroquine/

https://principia-scientific.org/a-tale-of-2-drugs-deep-state-chose-money-power-over-lives/

Excerpt:

Approximately $70 million in U.S. taxpayer funding began Gilead’s partnership with the U.S. Army, Centers for Disease Control and Prevention (CDC) and National Institutes of Health (NIH) to develop remdesivir. Initially for treating Ebola, it failed to show benefit and was shelved. If remdesivir is used to treat COVID-19, Gilead shareholders, not the taxpayers, will profit.

Early results of the first clinical trial of remdesivir against placebo in coronavirus showed modest benefits, according to The New York Times. Surviving patients given remdesivir were discharged four days sooner than patients given placebo, though no criteria were given for determining improvement. Death rates were not significantly different. About 25% of patients receiving remdesivir had potentially severe side effects, including multiple organ dysfunction, septic shock, acute kidney injury and low blood pressure. Another 23% showed evidence on lab tests of liver damage.

Gilead’s own press release revealed the side effect of acute respiratory failure in 6% of patients in the remdesivir five-day treatment group, and 10.7% of patients in the 10-day treatment group, clearly ominous findings with a drug designed to treat respiratory failure caused by COVID-19.

Dr. Steven Nissen, a Cleveland Clinic cardiologist who has conducted dozens of clinical trials, explained to The New York Times:

“The disclosure of trial results in a political setting, before peer review or publication, is very unusual. Scientists will need to see figures on harms associated with the drug in order to assess its benefits. … This is too important to be handled in such a sloppy fashion.”

Going back to 1997, Donald Rumsfeld chaired the Board of Directors at Gilead and after 2001 he held share packages valued at $5-25 Million. Gilead originally developed Tamiflu. George P Shultz, US Secretary of State also was on the board. He sold stocks at a value of more than $7 million. CA governor’s Pete Wilson’s wife also sat on the board.

“‘I don’t know of any biotech company that’s’ so politically well-connected [as Gilead],‘ Andrew McDonald, of the analyst firm Think Equity Partners, told Fortune.” (Source: “Virus Mania, How the Medical Industry Continually Invents Epidemics Making Billion Dollar Profits At Our Expense”)

It’s looking very much like the CDC is helping Gilead reclaim its losses on Remdesivir’s failure in Ebola.  Let’s just whip it back out for COVID-19, the public won’t notice!

For more:  https://madisonarealymesupportgroup.com/2020/05/11/what-are-sars-covid2-patients-really-dying-from/  Details are given within this link as to WHY HCQ works so well in COVID-19.  This is NOT a virus which causes interstitial pneumonia as we’ve been told, but rather it causes disseminated intravascular coagulation (DIC).  

https://madisonarealymesupportgroup.com/2020/04/04/efficacy-of-hydroxychloroquine-in-patients-with-covid-19-results-of-a-randomized-clinical-trial/

https://madisonarealymesupportgroup.com/2020/04/24/dr-oz-interviews-dr-didier-raoult-on-hydroxychloroquine-study-for-covid-19/

Dr. Zelenko, a New York doctor, has successfully treated 1,450 COVID-19 patients with a 99% success rate using a cocktail of hydroxychloroquine, Zinc Sulfate and Azithromycin:  https://techstartups.com/2020/04/21/dr-vladimir-zelenko-now-treated-1450-coronavirus-patients-2-deaths-using-hydroxychloroquine-99-99-success-rate-latest-video-interview/  Video with Zelenko in link.

https://madisonarealymesupportgroup.com/2020/04/08/peter-navarro-explodes-at-fauci-in-heated-showdown-over-hydroxychloroquine/

 

 

 

 

 

 

Category:

research, Treatment, Viruses